Industry News
03/19/2026BMS & Microsoft Collaborate on AI-Driven Early Detection of Lung Cancer InitiativeBristol Myers Squibb and Microsoft announced a collaboration to advance AI-driven early detection of lung cancer by integrating FDA-cleared radiology algorithms into Microsoft’s imaging platforms. The initiative aims to help clinicians identify lung nodules and diagnose cancer earlier, improve workflow efficiency, and expand access to early detection—particularly in underserved and rural communities. By combining oncology expertise with scalable AI infrastructure, the partnership seeks to improve diagnostic accuracy, accelerate follow-up care, and ultimately enhance patient outcomes while addressing disparities in lung cancer detection. Read More |
03/19/2026Update: SB536Senate Bill 536 (SB 536), initially expanded into a sweeping medical malpractice overhaul that would have significantly increased liability exposure, was scaled back following strong advocacy from physician organizations and stakeholders. The final conference report removed provisions to raise the malpractice cap, expand the statute of limitations, and add prejudgment interest, instead focusing on data collection from insurers to inform future policy decisions. This outcome preserves the current legal framework while setting the stage for more evidence-based malpractice reform discussions in Virginia. Read More |
03/12/2026SB536 Explodes the Medical Malpractice Cap! Oppose Today!Act Now!Earlier in the legislative session, Mark Obenshain introduced SB 536, which initially proposed allowing pre-judgment interest to be exempt from Virginia’s medical malpractice cap. As the bill moved through the legislature, it expanded significantly and now proposes more than doubling the malpractice cap—from $2.75 million in 2026 to $6 million starting in 2027. The bill is now headed to a conference committee, where lawmakers could rewrite it further. The Medical Society of Virginia (MSV) is urging physicians and supporters to contact their legislators and oppose any version of the bill that could increase financial pressures on physicians, hospitals, and healthcare providers. MSV argues that large increases to the cap could worsen financial strain on healthcare practices already facing economic challenges. Read More |
03/11/2026Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple MyelomaBristol Myers Squibb announced positive Phase 3 results from the SUCCESSOR-2 clinical trial, evaluating the oral investigational drug mezigdomide in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma. The study met its primary endpoint, showing the combination significantly improved progression-free survival compared with standard therapy alone, meaning patients experienced a longer period before their disease worsened. Researchers reported a safety profile consistent with previous studies and plan to present more detailed results at an upcoming medical meeting. Read More |
12/11/2025Virginia’s Prescription Drug Affordability Board needs guardrails to protect patient accessA recent commentary in the Virginia Mercury from Dr. Rich Ingram, VAHO President, highlights ongoing discussions around establishing a Prescription Drug Affordability Board (PDAB) in Virginia to address high prescription drug costs. While the goal of improving affordability is widely supported, the article emphasizes the importance of including safeguards—particularly if the board is authorized to set upper payment limits on certain medications. Without careful consideration of drug acquisition and administration costs, these limits could unintentionally make it difficult for providers to offer some treatments, particularly high-cost specialty medications such as those used in oncology. Policymakers are encouraged to ensure any affordability measures include protections that maintain patient access to needed therapies. Read More |
11/21/2025FDA approves (Zepzelca) lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancerOn October 2, 2025, the Food and Drug Administration approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals, Inc.) in combination with atezolizumab (Tecentriq, Genentech Inc.) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech Inc.) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin, and etoposide. Full prescribing information for Zepzelca, Tecentriq, and Tecentriq Hybreza will be posted on Drugs@FDA. Read More |
11/21/2025FDA approves (LIBTAYO) cemiplimab-rwlc for adjuvant treatment of cutaneous squamous cell carcinomaOn October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc.) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. Second FDA approval for TEVIMBRA in 2024 Read More |
11/21/2025FDA Approves BeiGene’s TEVIMBRA® (tislelizumab-jsgr) First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with ChemotherapyNew indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers Second FDA approval for TEVIMBRA in 2024 Read More |
12/27/2024FDA Approves BeiGene’s TEVIMBRA® (tislelizumab-jsgr) First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with ChemotherapyNew indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers Second FDA approval for TEVIMBRA in 2024 Read More |
12/27/2024FDA Approves Bristol Myers Squibb’s Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) IndicationsOpdivo Qvantig is the first and only subcutaneously administered PD-1 inhibitor Given over three- to five-minutes, Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to intravenous Opdivo in the Phase 3 CheckMate-67T trial Read More |
12/20/2024FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal CancerBRAFTOVI in combination with cetuximab and mFOLFOX6 is the first and only combination regimen with targeted therapy approved for use as early as first-line for patients with metastatic colorectal cancer with a BRAF V600E mutation Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the Phase 3 BREAKWATER trial Read More |
